Current Report Filing (8-k)
March 04 2021 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): February 26, 2021
ZOMEDICA CORP.
|
(Exact name of registrant as specified in its charter)
|
Alberta, Canada
|
|
001-38298
|
|
N/A
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
100 Phoenix Drive, Suite 125, Ann Arbor, Michigan
|
|
48108
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (734) 369-2555
Not Applicable
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Shares, without par value
|
ZOM
|
NYSE American
|
Item 4.01. Changes in Registrant’s
Certifying Accountants.
On February 26, 2021,
Zomedica Corp. (the “Company”) requested and the Audit Committee of the Board of Directors (the “Board”)
of the Company accepted the resignation of MNP LLP (“MNP”), the Company’s independent registered public accounting
firm, effective March 1, 2021 and recommended to the Board the engagement of Grant Thornton LLP (“Grant Thornton”)
as its new independent registered public accounting firm as of and for the year ended December 31, 2021. The Board has formally
appointed Grant Thornton to fill the vacancy created by the resignation of MNP. As described below, the change in independent registered public accounting
firm is not the result of any disagreement with MNP.
MNP’s audit
reports on the Company’s financial statements for the years ended December 31, 2019 and 2020 did not provide an adverse opinion
or disclaimer of opinion to the Company’s financial statements, nor modify its opinion as to uncertainty, audit scope or
accounting principles.
During the
fiscal years ended December 31, 2019 and 2020, and the subsequent interim periods through February 26, 2021, there were: (i)
no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company
and MNP on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure
which, if not resolved to MNP’s satisfaction, would have caused MNP to make reference thereto in their reports; and
(ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
During the fiscal
years ended December 31, 2019 and 2020 and the subsequent interim periods through February 26, 2021, neither the Company nor anyone
on its behalf has consulted with Grant Thornton regarding: (i) the application of accounting principles to a specific transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither
a written report nor oral advice was provided to the Company that Grant Thornton concluded was an important factor considered by
the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject
of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any reportable
event within the meaning of Item 304(a)(1)(v) of Regulation S-K.
The Company has provided
MNP with a copy of the disclosures in this Form 8-K and has requested that MNP furnish the Company with a letter addressed to the
Securities and Exchange Commission (“SEC”), stating whether it agrees with the statements made herein and if not, stating
in what respects it does not agree. A copy of MNP’s letter, dated March 4, 2021 is filed as Exhibit 16.1 to this Form 8-K.
Item 9.01. Financial Statements and
Exhibits.
(d) The following exhibit is furnished
with this report:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
ZOMEDICA CORP.
|
|
|
|
|
|
|
|
|
|
Date: March 4, 2021
|
|
By: /s/ Ann Marie Cotter
|
|
|
|
Name: Ann Marie Cotter
|
|
|
|
Title: Chief Financial Officer
|
|
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Apr 2023 to Apr 2024